Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427899 | 1.00 | GSK3B (0.41) | GSK3BCYP2D6PIK3R1PIK3CACYP1A2 | |
| SCHEMBL4425226 | 0.98 | GSK3B (0.41) | GSK3BCYP2D6PIK3R1PIK3CACYP1A2 | |
| SCHEMBL4425230 | 0.98 | GSK3B (0.41) | GSK3BCYP2D6PIK3R1PIK3CACYP1A2 | |
| SCHEMBL4421015 | 0.97 | GSK3B (0.42) | GSK3BCYP2D6PIK3R1PIK3CACYP1A2 | |
| SCHEMBL4421017 | 0.97 | GSK3B (0.42) | GSK3BCYP2D6PIK3R1PIK3CACYP1A2 | |
| SCHEMBL4430874 | 0.90 | GSK3B (0.41) | GSK3BCYP2D6PIK3R1PIK3CACYP1A2 | |
| SCHEMBL4430878 | 0.90 | GSK3B (0.41) | GSK3BCYP2D6PIK3R1PIK3CACYP1A2 | |
| SCHEMBL4425837 | 0.90 | GSK3B (0.43) | GSK3BCYP2D6PIK3R1PIK3CACYP1A2 | |
| SCHEMBL4425851 | 0.90 | GSK3B (0.43) | GSK3BCYP2D6PIK3R1PIK3CACYP1A2 | |
| SCHEMBL4425855 | 0.90 | GSK3B (0.43) | GSK3BCYP2D6PIK3R1PIK3CACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294631-B2 | Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | claimed |
| EP-1699795-B1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKLYMINE]-PYRIMIDO[1,2A]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2007-04-25 | — | — | EP | claimed |
| US-20070010539-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-01-11 | — | — | US | claimed |
| US-7547705-B2 | Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| US-7294631-B2 | Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| EP-1699795-B1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKLYMINE]-PYRIMIDO[1,2A]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2007-04-25 | — | — | EP | disclosed |
| US-20070010539-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010539-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | GSK3B 1/4885CYP2D6 2197/4885PIK3R1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.